We hypothesize that the drug uptake in CEA− tumors is primarily caused by CEA-IL2v binding to IL-2 receptor present on tumor infiltrating lymphocytes similarly to what has been reported for IL-2 therapy in melanoma, head and neck- and renal cell carcinoma [24–26]. The gene discussed is IL2; the disease is hereditary clear cell renal cell carcinoma.